** Shares of Israel-based drug developer Galmed Pharmaceuticals GLMD.O down 5.5% to $1.38
** Maxim Group cuts rating from to "hold" from "buy," and removes PT
** Downgrading GLMD due to the lack of clarity on the path forward and strategic positioning - Maxim
** GLMD may also potentially require a capital raise to commence a clinical trial; under current market conditions, financing will likely be difficult and significantly dilutive, Maxim says
** Up to last close, GLMD had fallen over 52% YTD
(Reporting by Juby Babu in Mexico City)
((Juby.Babu@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。